Kenta Biotech relocates to Zurich
May 29, 2012 in Medical Technology
BERN, SWITZERLAND – Kenta Biotech announced that it is relocating from Bern, Switzerland to Bio-Technopark in Zurich-Schlieren. In its new headquarters, Kenta Biotech will rent state-of-the-art laboratories, allowing it to boost research efforts and development of treatments for hospital-acquired infections.
Among the site’s advantages are its proximity to academic research centers in Zurich and the support provided by local authorities.
“This is definitely a strategic move for the company and we are now located at the best possible place for a young and innovative biotech company in Switzerland,” said Franco Merckling, CEO of Kenta Biotech.
Kenta Biotech has for six years developed technologies and products to fight hospital-acquired infections. With its relocation, officials say the company hopes to send a positive message to current and future investors and partners.